---
title: 'Optimism in inclusion body myositis: a double-blind randomised controlled
  phase III trial investigating the effect of sirolimus on disease progression in
  patients with IBM as measured by the IBM Functional Rating Scale'
date: '2025-02-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40018746/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250228171006&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: This phase IIb/III trial builds on prior findings to assess
  sirolimus''s potential in slowing or halting IBM progression, preserving patient
  function and independence, and advancing IBM therapeutic strategies and trial ...'
disable_comments: true
---
CONCLUSIONS: This phase IIb/III trial builds on prior findings to assess sirolimus's potential in slowing or halting IBM progression, preserving patient function and independence, and advancing IBM therapeutic strategies and trial ...